Phase I Clinical Study of Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of F527 in the Treatment of Patients With Relapsed or Refractory Lymphoma
Latest Information Update: 23 May 2024
At a glance
- Drugs F 527 (Primary)
- Indications Lymphoma
- Focus Adverse reactions
- Sponsors Shandong New Time Pharmaceutical Co LTD
Most Recent Events
- 30 Mar 2022 New trial record